NuSight Medical has introduced The NuLids System, a doctor-prescribed, home-use medical device that efficiently treats dry eye by gently stimulating, de-capping, and rejuvenating the meibomian glands to a healthier state.
The system was introduced at the American Optometric Association meeting in Denver.
“NuLids is a win-win for treating dry eye” Rob Foster, President & CEO, NuSight Medical, said in a company news release. “Patients benefit from improved tear film stability, comfort, and lubrication that combat dry eye. Doctors gain an important therapy while helping to build their practice. And, because NuLids is sold only through licensed eye care practitioners, doctors are in control of the therapy while patients perform the treatment at home, improving practice efficiency.”
“About 86% of dry eye patients have compromised Meibomian gland function which results in an unstable tear film and subsequent premature breakdown of the tear,” John Olkowski, MD, Founder and Chairman of NuSight Medical, said in the news release. “The oil produced by the Meibomian glands forms an effective barrier to tear evaporation. With NuLids aiding the production and flow of meibum, the clinical signs and symptoms of dry eye are significantly reduced.”
In a recent multicenter clinical study, the NuLids System demonstrated a 65% improvement in Tear Breakup Time and an 81% improvement in Meibomian Glands Yielding Liquid Secretions. The vast majority of patients reported a two-fold improvement in their dry eye symptoms after only two weeks of daily use.
NuLids can be complementary with in-office procedures performed by eye doctors. Patients like the NuLids System because it is safe, effective, and easy to use without any known side effects. They also appreciate that it is cost effective and may reduce the need for expensive OTC lubricants and/or co-payments for pharmaceuticals.
NuLids takes only 60 seconds per day to use and patients quickly adapt to the simple routine. The NuLids I and NuLids II clinical studies found that 95% of patients surveyed after the 30 day trial reported being either “satisfied” or “very satisfied” with the overall treatment.”